Skip to main content

Redx income rises to £2.8m

Redx income rises to £2.8m

Redx Pharma is expecting its total income for the financial year ended September 30 to be £2.8m. The Liverpool and Alderley Park-based firm is reporting good progress over the second half of the financial year with expenditure in line with budgets and income growing from £2m in the first six months to March 31.

Redx, which several weeks ago announced a cancer research collaboration with international life science group Horizon Discovery Group to develop a pan-RAF inhibitor programme for colorectal cancer – the fourth most common cancer and the second most cause of deal from the disease in the UK – is in “encouraging discussions” over further commercial collaborations.

See article in full at TheBusinessDesk.com